Activators of SGK-1 for Use as Cardioprotective Agents
AssigneeGeorgia Regents University
InventorsMahmood Mozaffari, Babak Baban
Life of this patent
Estimating the term…
Abstract
Compositions for activating SGK-1 are provided. SGK-1 activators can be identified by the methods of screening provided herein. The SGK-1 activators can be used in the disclosed methods of reducing cell death and methods of treating ischemic-reperfusion injury. The ischemic-reperfusion injury can be due to a variety of complications resulting in blood loss to tissue and then the re-establishment of blood flow to the tissue.
Claims14
A method for reducing or inhibiting ischemic or ischemic-reperfusion injury in a subject comprising administering to the subject an effective amount of an SGK-1 activator to increase the levels of phosphorylated SGK-1 in endothelial or cardiac tissue of the subject.
A method for screening for activators of SGK-1 comprising determining the ability of a test compound to modulate the expression, phosphorylation or activity of SGK-1.
A method of reducing cell death comprising contacting an injured or diseased tissue with a therapeutically effective amount of an SGK-1 activator.
A method of preventing or treating an ischemic-reperfusion injury comprising administering to a subject a composition comprising a therapeutically effective amount of an SGK-1 activator following myocardial infarction or primary reperfusion therapy.
A pharmaceutical composition comprising a therapeutically effective amount of an SGK-1 activator to increase levels of phosphorylated SGK-1 in endothelial or cardiac tissue of a subject and a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.